Arrowhead Pharmaceuticals, Inc. Sustainability Profile
Arrowhead Pharmaceuticals, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on the development of transformative medicines for the treatment of serious diseases. Founded in 2008, Arrowhead has made significant strides in the field of RNA interference (RNAi) therapeutics, positioning itself as a leader in this innovative industry. With a strong emphasis on precision medicine, Arrowhead's core products include ARO-HBV and ARO-AAT, which target chronic hepatitis B and alpha-1 antitrypsin deficiency, respectively. These therapies are distinguished by their ability to silence disease-causing genes, offering unique treatment options that address unmet medical needs. Arrowhead's commitment to advancing healthcare is reflected in its robust pipeline and strategic partnerships, solidifying its market position as a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Arrowhead Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Arrowhead Pharmaceuticals, Inc.'s score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Arrowhead Pharmaceuticals, Inc.'s reported carbon emissions
Arrowhead Pharmaceuticals, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Arrowhead Pharmaceuticals may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, it remains essential for companies like Arrowhead to consider developing and communicating their climate strategies to align with global efforts in reducing greenhouse gas emissions.
How Carbon Intensive is Arrowhead Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Arrowhead Pharmaceuticals, Inc.'s Location?
Arrowhead Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Arrowhead Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
